Lilly wagers almost $1B on Rigel's drugs for immune and nervous systems

Lilly wagers almost $1B on Rigel's drugs for immune and nervous systems

Source: 
BioPharma Dive
snippet: 

Eli Lilly has agreed to pay $125 million for an exclusive license to an experimental drug from Rigel Pharmaceuticals that the companies believe could be valuable in the treatment of autoimmune and inflammatory diseases.